{
  "docId": "019de070-7de1-7343-8d2f-5d51a9877c50",
  "docSlug": "ff3158b4501b6094038126272ca46097",
  "documentTitle": "BioAtla | IPO Presentation Deck | 31 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 11,
  "pageCount": 31,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "why_now",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 5,
  "notes": "The slide uses a logical flow from unmet need to regulatory advantage to commercial validation.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de070-7de1-7343-8d2f-5d51a9877c50/11",
  "deckHref": "/decks/019de070-7de1-7343-8d2f-5d51a9877c50",
  "deckJsonHref": "/decks/019de070-7de1-7343-8d2f-5d51a9877c50.json",
  "deckAnchorHref": "/decks/019de070-7de1-7343-8d2f-5d51a9877c50#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.02,
        "y": 0.4
      },
      "kind": "callout",
      "text": "~57% of our Sarcoma patients are AXL positive (TmPS ≥ 70), supporting AXL opportunity",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "04401c24-744a-4372-8b8b-d0acffa070ed",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.02,
        "y": 0.15
      },
      "kind": "callout",
      "text": "Unmet need drives lower regulatory hurdles and higher market demand, representing opportunity",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "16881f1c-b284-4b96-b9fa-16ed5943f4b3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.02,
        "y": 0.65
      },
      "kind": "callout",
      "text": "BA3011 (AXL-ADC) has high potential to treat sarcoma successfully and fulfill opportunity",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ff5d881e-4a2d-4b15-aae3-8bd296392cd2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.65,
        "x": 0.3,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Lower Regulatory Hurdles for Sarcoma Treatments: Approved therapies generally show improved ORRs of less than 15%",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f58ccc9a-21ac-45ce-96c7-7b0bdea4c6b6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "Note: TmPS= Tumor membrane Percent Score- Scores range from 0 to 100; Objective response rates (ORR) is defined as the proportion of patients with tumor size reduction of a predefined amount and for a minimum time period and is comprised of complete responses and partial responses; Pembrolizumab ORR data from 2015-2016 Pembrolizumab ORR data from 2017 ORR for Gemcitabine treatment in combination with Docetaxel",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1526b5cd-9d5d-46e7-8da0-35b2e401a4df",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.65,
        "x": 0.3,
        "y": 0.15
      },
      "kind": "list",
      "text": "Unmet Need for Sarcomas: Bone sarcomas have no approved therapies after failure of frontline regimens; No targeted therapies available for most soft tissue sarcoma; Low 5-year survival rates (~16.4% for late-stage metastatic soft tissue sarcoma)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "87bede50-9a57-46f3-b651-a2e73ce37513",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.65,
        "x": 0.3,
        "y": 0.7
      },
      "kind": "list",
      "text": "Large and Under-Appreciated Commercial Opportunity: Lilly's olaratumab given accelerated approval for combination treatment for sarcoma in 2016; Before withdrawal from market for failing Phase 3, olaratumab had sales of $562 million with a 50% CAGR, in less than 2 years",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec1284be-1b2e-439b-99b3-70ac553f21d3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "AXL Targeting: Opportunity to Fill Treatment Void in Sarcomas",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee786380-38ae-44cd-bb0c-7e39bc22b937",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "causal-chain",
      "slug": null,
      "matchId": "9929edfd-309d-4794-b975-281da689c610",
      "evidence": "The slide links unmet need -> regulatory hurdles -> commercial opportunity -> product potential.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 11,
      "from": 10,
      "beatId": "2ba97b7f-6c61-4640-8d6e-2734585ceb20",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The document presents market sizing information on pages 10-11.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 15,
      "from": 11,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "e68a7a0d-6e24-461d-8cb2-101d25fdd683",
      "evidence": "The document presents information on the current market opportunity and the company's progress on pages 11-15.",
      "position": 1,
      "objective": "Why is now the right time to invest in BioAtla?",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.6,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}